Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Computational immunogenomic approaches to predict response to cancer immunotherapies
Venkateswar Addala, Felicity Newell, John V. Pearson, et al.
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 28-46
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Multi-OMICS approaches in cancer biology: New era in cancer therapy
Sohini Chakraborty, Gaurav Sharma, Sricheta Karmakar, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 5, pp. 167120-167120
Closed Access | Times Cited: 41
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
Leisha A. Emens, Pedro Romero, Ana C. Anderson, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009063-e009063
Open Access | Times Cited: 25
Malignant Melanoma: An Overview, New Perspectives, and Vitamin D Signaling
Radomir M. Slominski, Tae‐Kang Kim, Zorica Janjetović, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2262-2262
Open Access | Times Cited: 17
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Zhaokai Zhou, Jiahui Wang, Jiaojiao Wang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
Kathleen E. Houlahan, Aziz Khan, Noah F. Greenwald, et al.
Science (2024) Vol. 384, Iss. 6699
Open Access | Times Cited: 8
Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization
Luchen Chang, Jiamei Liu, Jialin Zhu, et al.
Cancer Biology and Medicine (2025), pp. 1-15
Open Access | Times Cited: 1
Single cell sequencing revealed the mechanism of CRYAB in glioma and its diagnostic and prognostic value
Hua-Bao Cai, Meng-Yu Zhao, Xin-Han Li, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 5
Artificial intelligence and neoantigens: paving the path for precision cancer immunotherapy
Alla Bulashevska, Zsófia Nacsa, Franziska Lang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
The clinical application of artificial intelligence in cancer precision treatment
Jinyu Wang, Ziyi Zeng, Zehua Li, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Comprehensive analysis of lipid metabolic signatures identified CEBPD promotes breast cancer cell proliferation
Yu Zhao, Huan He, Linyan Huang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Overview on biomarkers for immune oncology drugs
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Five latent factors underlie response to immunotherapy
Joseph Usset, Axel Rosendahl Huber, Maria Andrianova, et al.
Nature Genetics (2024) Vol. 56, Iss. 10, pp. 2112-2120
Open Access | Times Cited: 4
Identifying specific TLS-associated genes as potential biomarkers for predicting prognosis and evaluating the efficacy of immunotherapy in soft tissue sarcoma
Xiang-Xu Wang, Yunpeng Liu, Yajie Lu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Unveiling the molecular complexity of proliferative diabetic retinopathy through scRNA-seq, AlphaFold 2, and machine learning
Jun Wang, Hongyan Sun, Lisha Mou, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 3
Protein isoform-centric therapeutics: expanding targets and increasing specificity
Peter Kjer-Hansen, Tri Giang Phan, Robert J. Weatheritt
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 10, pp. 759-779
Closed Access | Times Cited: 3
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade
Theinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 45
Open Access | Times Cited: 3
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade
Theinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton
Abir Hussein, Slava Stamova, Maria Xydia, et al.
Cancer Cell (2024) Vol. 42, Iss. 6, pp. 938-941
Closed Access | Times Cited: 2
Multimodal data fusion AI model uncovers tumor microenvironment immunotyping heterogeneity and enhanced risk stratification of breast cancer
Yunfang Yu, Gengyi Cai, Ruichong Lin, et al.
MedComm (2024) Vol. 5, Iss. 12
Open Access | Times Cited: 2
Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype
Pascal Jézéquel, Hamza Lasla, Wilfried Gouraud, et al.
Breast Cancer (2024) Vol. 31, Iss. 5, pp. 825-840
Closed Access | Times Cited: 1
MOCS, a novel classifier system integrated multimoics analysis refining molecular subtypes and prognosis for skin melanoma
Juelan Ye, Fuchun Liu, Luoshen Zhang, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-17
Open Access
Special Issue “Cancer Immunotherapy: Tumor Microenvironment, Biomarker Discovery and Immune Resistance”
Jason Yongsheng Chan
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5113-5113
Open Access
Germline variants alter immune surveillance
Nicola Waddell, Venkateswar Addala
Science (2024) Vol. 384, Iss. 6699, pp. 961-962
Closed Access
Page 1 - Next Page

Scroll to top